World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
76
Citations
19510
World Ranking
1921
National Ranking
939

Overview

Hideho Okada is affiliated with the University of California, San Francisco in the United States. Their research portfolio primarily spans the fields of Medicine and Immunology and Microbiology, with significant contributions to the subfields of Oncology, Immunology, Genetics, Molecular Biology, and Biomedical Engineering.

Their scholarly work concentrates on topics related to CAR-T cell therapy research, glioma diagnosis and treatment, immunotherapy and immune responses, cancer immunotherapy and biomarkers, immune cells in cancer, virus-based gene therapy research, and nanowire synthesis and applications.

Okada's frequent publication venues include Neuro-Oncology, Cancer Research, Regular and Young Investigator Award Abstracts, bioRxiv (Cold Spring Harbor Laboratory), and the Journal for ImmunoTherapy of Cancer.

Collaborative work features several frequent co-authors, such as Takahide Nejo, Akane Yamamichi, Payal Watchmaker, Marco Gallus, and Senthilnath Lakshmanachetty.

Their recent papers include:

  • SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma (2021, Science Translational Medicine)
  • RASA2 ablation in T cells boosts antigen sensitivity and long-term function (2022, Nature)
  • Discovering dominant tumor immune archetypes in a pan-cancer census (2021, Cell)
  • Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective (2024, Cell)
  • Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma (2020, Journal of Clinical Investigation)

Best Publications

  • A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

    Donald M. O’Rourke;MacLean P. Nasrallah;Arati Desai;Jan J. Melenhorst

  • Actively personalized vaccination trial for newly diagnosed glioblastoma

    Norbert Hilf;Sabrina Kuttruff-Coqui;Katrin Frenzel;Valesca Bukur

  • Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

    Hideho Okada;Pawel Kalinski;Ryo Ueda;Aki Hoji

  • Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

    Hideho Okada;Michael Weller;Raymond Huang;Gaetano Finocchiaro

  • Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment

    Sören Müller;Gary Kohanbash;S. John Liu;Beatriz Alvarado

  • Classification of current anticancer immunotherapies

    Lorenzo Galluzzi;Erika Vacchelli;José Manuel Bravo-San Pedro;Aitziber Buqué

  • Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma

    Laura A. Johnson;John Scholler;Takayuki Ohkuri;Akemi Kosaka

  • SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma

    Joseph H. Choe;Payal B. Watchmaker;Milos S. Simic;Ryan D. Gilbert

  • COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells

    Mitsugu Fujita;Gary Kohanbash;Wendy Fellows-Mayle;Ronald L. Hamilton

  • Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

    Gary Kohanbash;Diego A. Carrera;Shruti Shrivastav;Brian J. Ahn

  • Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models

    Xinmei Zhu;Fumihiko Nishimura;Kotaro Sasaki;Mitsugu Fujita

  • STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment

    Takayuki Ohkuri;Arundhati Ghosh;Akemi Kosaka;Jianzhong Zhu

  • RASA2 ablation in T cells boosts antigen sensitivity and long-term function

    Unknown

  • Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas

    Ian F. Pollack;Regina I. Jakacki;Lisa H. Butterfield;Ronald L. Hamilton

  • Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy

    Xinmei Zhu;Mitsugu Fujita;Linda A. Snyder;Hideho Okada

  • Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy.

    Zinal S. Chheda;Gary Kohanbash;Gary Kohanbash;Kaori Okada;Naznin Jahan

  • GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-α

    Gary Kohanbash;Kayla McKaveney;Masashi Sakaki;Ryo Ueda

  • Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1

    Ryo Ueda;Gary Kohanbash;Kotaro Sasaki;Mitsugu Fujita

  • EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.

    Manabu Hatano;Junichi Eguchi;Tomohide Tatsumi;Naruo Kuwashima

  • Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity

    Tomohide Tatsumi;Jian Huang;William E. Gooding;Andrea Gambotto

  • Immunotherapeutic Approaches for Glioma

    Hideho Okada;Gary Kohanbash;Xinmei Zhu;Edward R. Kastenhuber

Frequent Co-Authors

Ian F. Pollack
Ian F. Pollack University of Pittsburgh
Walter J. Storkus
Walter J. Storkus University of Pittsburgh
Lisa H. Butterfield
Lisa H. Butterfield University of California, San Francisco
Ronald L. Hamilton
Ronald L. Hamilton University of Pittsburgh
Michael T. Lotze
Michael T. Lotze University of Pittsburgh
Pawel Kalinski
Pawel Kalinski Roswell Park Comprehensive Cancer Center
Carl H. June
Carl H. June University of Pennsylvania
Simon C. Watkins
Simon C. Watkins University of Pittsburgh
Theresa L. Whiteside
Theresa L. Whiteside University of Pittsburgh
Marcela V. Maus
Marcela V. Maus Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing related nursing degrees can expand career opportunities, especially in acute care and clinical research. Transitioning to an advanced role such as an Acute Care Nurse Practitioner is possible through specialized acnp programs, which prepare nurses to manage critically ill patients and work closely with immunology specialists.

Accelerated programs offer a fast track for those aiming to become nurse practitioners. Consider exploring a nurse practitioner accelerated program that combines rigorous coursework with clinical experience, enabling quicker entry into specialized healthcare roles associated with immunology.

For individuals without a nursing background, online pathways such as online absn programs for non nurses provide accessible routes to enter the nursing field and eventually specialize in immunology-related care.

Additionally, some may seek the easiest entry points via easiest accelerated nursing programs to get into. These programs can offer a practical starting point for building essential skills before moving into advanced immunology-focused roles.

Best Scientists Citing Hideho Okada

Trending Scientists